Mirum director granted DSUs and stock options
Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options. He received 1,980 deferred stock units and options for 3,772 shares of common stock at an exercise price of $101.00 per share, all as compensation awards.
The options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service.
Insider Trade Summary
Grant/Award: 5,752 shares
Grant/Award
2 txns
Insider
Fairey William
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 3,772 | $0.00 | $0.00 |
| Grant/Award | Deferred Stock Units | 1,980 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 3,772 contracts (Direct);
Deferred Stock Units — 1,980 contracts (Direct)
Footnotes (2)
- F1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
- F2. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Key Figures
Deferred stock units granted: 1,980 units
Stock options granted: 3,772 options
Option exercise price: $101.00 per share
+3 more
6 metrics
Deferred stock units granted
1,980 units
Grant to director William Fairey on 2026-06-15
Stock options granted
3,772 options
Grant to director William Fairey on 2026-06-15
Option exercise price
$101.00 per share
Stock Option (right to buy) underlying common stock
Option expiration
2036-06-14
Expiration date for stock options granted
Vesting schedule
First anniversary of grant
Awards fully vested by 2027 annual stockholder meeting
DSU payout triggers
Change in control or separation
Payout in stock upon earliest of these events
Key Terms
Deferred Stock Units, Stock Option (right to buy), change in control, annual stockholder meeting, +1 more
5 terms
Deferred Stock Units financial
"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 101.0000 per share"
change in control financial
"paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual stockholder meeting financial
"in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
separation from service financial
"within 60 days following separation from service with the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mirum Pharmaceuticals (MIRM) report for William Fairey?
Mirum reported that director William Fairey received equity compensation awards, including 1,980 deferred stock units and stock options for 3,772 shares. These are grants, not open-market purchases or sales, and reflect standard non-cash board compensation at Mirum Pharmaceuticals.
How many deferred stock units did William Fairey receive from Mirum (MIRM)?
William Fairey received 1,980 deferred stock units from Mirum Pharmaceuticals. Each deferred stock unit represents a contingent right to receive one share of common stock once vesting and specified payment conditions, such as a change in control or separation from service, are met.
What stock options were granted to William Fairey by Mirum Pharmaceuticals (MIRM)?
Mirum granted William Fairey stock options covering 3,772 shares of common stock at an exercise price of $101.00 per share. These options vest on the first anniversary of the grant date and will be fully vested by the company’s 2027 annual stockholder meeting.
When do William Fairey’s Mirum (MIRM) deferred stock units and options vest?
Both the deferred stock units and stock options granted to William Fairey vest on the first anniversary of the grant date. The awards will in any case be fully vested on the date of Mirum Pharmaceuticals’ 2027 annual stockholder meeting, according to the filing.
Under what conditions are Mirum (MIRM) deferred stock units paid out to William Fairey?
Each vested deferred stock unit will be paid out in Mirum common stock upon the earliest of a change in control of the company or within 60 days following William Fairey’s separation from service, providing equity-based compensation aligned with his continued board service.
Are William Fairey’s Mirum (MIRM) equity awards open-market purchases or sales?
No, the reported transactions are compensation grants, not open-market trades. The Form 4 identifies them with code “A” as grant, award, or other acquisition, indicating board-related equity compensation rather than discretionary buying or selling of Mirum stock in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates